---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-015550"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:47:58.585999+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics raises $1.2M via Series C Convertible Redeemable Preferred Stock offering

## Summary
- Sold 50,000 shares of Series C Preferred at $24/share for $1.2M total to an accredited investor.
- Series C carries 5% annual dividend, convertible at lower of $0.182 or market price, floor $0.037.
- Redemption at 110% of stated value ($27) after 60 days up to 365 days from issue.
- Special meeting on March 20, 2023 to seek stockholder approval for authorized share increase and reverse stock split.
- Registration rights agreement requires filing; failure triggers 2% monthly liquidated damages on subscription amount.

## SEC filing metadata
- accession: 0001213900-23-015550
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390023015550/0001213900-23-015550-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390023015550/ea174273-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-015550
- JSON: https://secwatch.observer/filing/0001213900-23-015550.json
- Plain text: https://secwatch.observer/filing/0001213900-23-015550.txt

## Key facts
- Governance Changes
  Allarity Therapeutics, Inc.: Filed Certificate of Designation of Series C Preferred Stock (effective 2023-02-24).
  - Change: charter amendment
  - Effective: 2023-02-24
  source text: Pursuant to the terms of the SPA, on February 24, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock (the “Series C COD”) with the Delaware Secretary of State designating 50,000 shares of its authorized and unissued preferred stock as Series C Preferred Stock with a stated value of $27.00 per share (the “Stated Value”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023015550/0001213900-23-015550-index.htm
- Governance Changes
  Allarity Therapeutics, Inc.: Filed certificate of amendment to Series C COD to clarify conversion price and floor price (effective 2023-02-28).
  - Change: charter amendment
  - Effective: 2023-02-28
  source text: On February 28, 2023, the Company filed a certificate of amendment to the Series C COD (the “COD Amendment”) to clarify the terms of conversion price and floor price based on definitions provided in the Series C COD
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023015550/0001213900-23-015550-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.